This suggests that inhibition of PP2Ac may be a potential therapy for NAFLD, which is associated with pathologies, such as insulin resistance and increased hepatic lipid accumulation [42]. This evidence concerns the gene PPP2CA and metabolic dysfunction-associated steatotic liver disease.